News

Spanish regulators have signed off on Oryzon Genomics’ plan to conduct a Phase 2 clinical trial of its Alzheimer’s therapy ORY-2001. The ETHERAL trial, which will cover patients with mild to moderate forms of the disease, will be the first to assess the effectiveness of an epigenetic therapy for Alzheimer’s. This approach…

The brain works in a coordinated matter, like a tuned orchestra, scientists say. If a single instrument is out of sync, it affects the entire ensemble. In Alzheimer’s disease, damage to certain nerve cells is sufficient to alter brainwave rhythms and cause a loss of cognitive function. A new mouse study shows how…

The transportation service Lyft is teaming up with the Global Alzheimer’s Platform Foundation to help those who are participating in an Alzheimer’s trial get to and from U.S. and Canadian research sites. Under the agreement, Lyft will provide transportation for those taking part in Eli Lilly’s Phase 2 TRAILBLAZER-ALZ (NCT03367403) trial and their…

A form of vitamin B3 was found to prevent brain damage and improve memory and physical function in a new mouse model of Alzheimer’s disease, suggesting a possible new target for treatment. Mice given ChromaDex’s Niagen (nicotinamide riboside, or NR) — a unique member of the vitamin B3 family…

Cognition Therapeutics’ lead investigative therapy Elayta (CT1812) shows promise in improving the activity of brain cells in patients with Alzheimer’s disease, according to the results of a Phase 1b/2a trial. Elayta is a small molecule that displaces amyloid-beta oligomers formed in Alzheimer’s disease from their binding sites, or…

The total cost to care for people living with Alzheimer’s disease and other dementias is projected to surpass a quarter of a trillion dollars in 2018 for the second consecutive year, according to a report from the Alzheimer’s Association. The organization’s recently released 2018 Alzheimer’s Disease Facts and…

Investigational therapy Neflamapimod led to significant improvements in episodic memory function in patients with early Alzheimer’s disease, results from EIP Pharma’s Phase 2a clinical trial show. “Significant unmet need exists for improved Alzheimer’s treatments which is why we are so encouraged…

Bryostatin, Neurotrope Bioscience’s investigational therapy, was associated with improved cognition in advanced Alzheimer’s disease patients in post-hoc (after-the-fact) analysis of a Phase 2 trial. Results from this study were presented at the Sachs’ Neuroscience Innovation Forum on Jan. 7 in San Francisco, California. Bryostatin-1 is a compound known as…

A new algorithm can quantify faster and more effectively the amount of brain amyloid plaques during positron emission tomography (PET) scans for use in subject stratification and clinical trials of Alzheimer’s disease, according to the developers. The new technique, developed by Invicro, was presented earlier this year at the…

Roche soon will start two Phase 3 trials testing gantenerumab, its amyloid-targeting treatment candidate, in prodromal, or early, Alzheimer’s patients. Each plans to enroll 750 people, ages 50 to 90, and will judge gantenerumab’s effectiveness and potential clinical benefit by looking at changes in dementia and amyloid plaque load…